Open AccessTargeting the dendritic cell: the key to immunotherapy in cancer?
Author(s) -
Faith A.,
Hawrylowicz C. M.
Publication year - 2005
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.2005.02737.x
Subject(s) - immunotherapy , immunology , dendritic cell , cancer , cancer immunotherapy , key (lock) , tumor immunology , medicine , biology , immune system , ecology
Immunotherapy denotes a strategy for manipulating a patient's immune response [1]. In cancer or infectious disease the approach is designed to boost the patient's response to tumour antigens or pathogens. Conversely, immunotherapeutic strategies in autoimmunity or allergy are designed to silence the patient's response to autoantigens or allergens. Two principal approaches to immunotherapy, modulation of the immune system de novo by therapeutic vaccination or administration of exogenous reagents, such as cytokines and antibodies, in order to boost endogenous immune function, have been described [2].